Egfr and kras mutations
作者： Kenneth J. Hillan
DOI:
关键词:
摘要: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS methods of detecting such as well prognostic method for identifying a tumors that are susceptible anticancer therapy chemotherapy and/or kinase inhibitor treatment. involve determining the presence mutated EGFR gene or protein tumor sample.
lens.org 参考文章(17)
Thomas Metz, Alexander Fleischmann, Erwin Wagner, Maria Sibilia, Axel Behrens, Novel use of inhibitors of the epidermal growth factor receptor ,(2001)
Robert Crichton, Jean-Pierre Lenders, Octavian Anton, Immobilized enzymes, processes for preparing same and use thereof ,(1985)
Anthony T. Yeung, Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands ,(1996)
D. Eberhard, B. Johnson, A. Goddard, R. Herbst, P. Janne, D. Johnson, P. Klein, M. Ostland, S. Seshagiri, K. Hillan, O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib Lung Cancer. ,vol. 49, ,(2005) , 10.1016/S0169-5002(05)80320-4
M. Reck, A. Heller, D. Foernzler, J. Moecks, C. Ward, F. De Rosa, G. Sauter, U. Brennscheidt, U. Gatzemeier, PD-155 Molecular markers such as EGFR and kRAS mutations aspredictors of sensitivity to erlotinib in patients (pts) with NSCLC: Exploratory subanalyses of TALENT, a phase III trial Lung Cancer. ,vol. 49, ,(2005) , 10.1016/S0169-5002(05)80488-X
Bert Vogelstein, Darell Bigner, Structural alterations of the egf receptor gene in human gliomas ,(1990)
G SPEAKE, B HOLLOWAY, G COSTELLO, Recent developments related to the EGFR as a target for cancer chemotherapy Current Opinion in Pharmacology. ,vol. 5, pp. 343- 349 ,(2005) , 10.1016/J.COPH.2005.02.007
L.C. AMLER, A.D. GODDARD, K.J. HILLAN, Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Cold Spring Harbor Symposia on Quantitative Biology. ,vol. 70, pp. 483- 488 ,(2005) , 10.1101/SQB.2005.70.048
Shuji Ogino, Jeffrey A. Meyerhardt, Mami Cantor, Mohan Brahmandam, Jeffrey W. Clark, Chungdak Namgyal, Takako Kawasaki, Kate Kinsella, Ann L. Michelini, Peter C. Enzinger, Matthew H. Kulke, David P. Ryan, Massimo Loda, Charles S. Fuchs, Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer Clinical Cancer Research. ,vol. 11, pp. 6650- 6656 ,(2005) , 10.1158/1078-0432.CCR-05-0738
William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus, KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib PLOS Medicine. ,vol. 2, ,(2005) , 10.1371/JOURNAL.PMED.0020017